gsk 1440115
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01202214)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Urotensin-2ANTAGONIST
UTS2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4'-(1-(((6,7-dichloro-3- oxo-2,3-dihydro-4h-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-biphenylcarboxylic acid
- gsk1440115
- gsk1440115
- gsk1440115
- gsk 1440115
- gsk-1440115
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01424280 | Phase 1 | Aug 1, 2011 | Accenture |
| NCT01202214 | Phase 1 | Sep 1, 2010 | Accenture |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Accenture | For profit | 2 | 2 | 1 | 2010 |
1 organizations
Page 1 / 1